A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Zhao, Hanjun ^a   Zhou, Jie ^a   Zhang, Ke ^a   Chu, Hin ^a   Liu, Dabin ^a   Poon, Vincent Kwok Man ^a   Chan, Chris Chung Sing ^a   Leung, Ho Chuen ^a   Fai, Ng ^a   Lin, Yong Ping ^a   Zhang, Anna Jin Xia ^a   Jin, Dong Yan ^a   Yuen, Kwok Yung ^a   Zheng, Bo Jian ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BETA DEFENSIN; DEFB4 PROTEIN, MOUSE; PEPTIDE; PEPTIDE FRAGMENT; PROTEIN BINDING; VIRUS ENVELOPE PROTEIN;

ANIMAL; CHEMISTRY; DRUG EFFECTS; ENDOSOME; IC50; INFLUENZA A VIRUS; METABOLISM; MICROBIAL SENSITIVITY TEST; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MORTALITY; MOUSE; ORTHOMYXOVIRIDAE INFECTIONS; PATHOLOGY; PHYSIOLOGY; SARS CORONAVIRUS; VIROLOGY; VIRUS LOAD;

ANIMALS; ANTIVIRAL AGENTS; BETA-DEFENSINS; ENDOSOMES; INFLUENZA A VIRUS; INHIBITORY CONCENTRATION 50; MICE; MICROBIAL SENSITIVITY TESTS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; ORTHOMYXOVIRIDAE INFECTIONS; PEPTIDE FRAGMENTS; PEPTIDES; PROTEIN BINDING; SARS VIRUS; VIRAL ENVELOPE PROTEINS; VIRAL LOAD;

EID: 84959422192     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep22008     Document Type: Article

References (40)

1. Horimoto T., & Kawaoka Y. Influenza: lessons from past pandemics, warnings from current incidents. Nat Rev Microbiol 3, 591-600 (2005
2. WHO. Influenza at the human-animal interface. Summary and assessment as of December 14 2015. http://www.who.int/influenza/human-animal-interface/Influenza-Summary-IRA-HA-interface-14-Dec-2015.pdf? ua= 1. (Accessed: 20th December 2015
3. Watanabe T., Watanabe S., Maher E. A., Neumann G., & Kawaoka Y. Pandemic potential of avian influenza A (H7N9) viruses. Trends Microbiol 22, 623-31 (2014
4. Du L., et al. The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat Rev Microbiol 7, 226-36 (2009
5. Zumla A., Hui D. S., & Perlman S. Middle East respiratory syndrome. Lancet (2015
6. Castle S. C. Clinical relevance of age-related immune dysfunction. Clin Infect Dis 31, 578-85 (2000
7. Luscher-Mattli M. Influenza chemotherapy: a review of the present state of art and of new drugs in development. Arch Virol 145, 2233-48 (2000
8. Zimmermann G. R., Legault P., Selsted M. E., & Pardi A. Solution structure of bovine neutrophil beta-defensin-12: the peptide fold of the beta-defensins is identical to that of the classical defensins. Biochemistry 34, 13663-71 (1995
9. Valore E. V., et al. Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. J Clin Invest 101, 1633-42 (1998
10. Bals R., et al. Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest 102, 874-80 (1998
11. Quinones-Mateu M. E., et al. Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS 17, F39-48 (2003
12. Leikina E., et al. Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins. Nat Immunol 6, 995-1001 (2005
13. Ryan L. K., et al. Modulation of human beta-defensin-1 (hBD-1) in plasmacytoid dendritic cells (PDC), monocytes, and epithelial cells by influenza virus, Herpes simplex virus, and Sendai virus and its possible role in innate immunity. J Leukoc Biol 90, 343-56 (2011
14. Klotman M. E., & Chang T. L. Defensins in innate antiviral immunity. Nat Rev Immunol 6, 447-56 (2006
15. Ding J., Chou Y. Y., & Chang T. L. Defensins in viral infections. J innate immun 1, 413-20 (2009
16. Feng Z., Dubyak G. R., Lederman M. M., & Weinberg A. Cutting edge: human beta defensin 3-a novel antagonist of the HIV-1 coreceptor CXCR4. J Immunol 177, 782-6 (2006
17. Sun L., et al. Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection. J Virol 79, 14318-29 (2005
18. Kota S., et al. Role of human beta-defensin-2 during tumor necrosis factor-alpha/NF-kappaB-mediated innate antiviral response against human respiratory syncytial virus. J Biol Chem 283, 22417-29 (2008
19. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 415, 389-95 (2002
20. Bai Y., et al. Structure-dependent charge density as a determinant of antimicrobial activity of peptide analogues of defensin. Biochemistry 48, 7229-39 (2009
21. Matlin K. S., Reggio H., Helenius A., & Simons K. Infectious entry pathway of influenza virus in a canine kidney cell line. J Cell Biol 91, 601-13 (1981
22. Lakadamyali M., Rust M. J., Babcock H. P., & Zhuang X. Visualizing infection of individual influenza viruses. Proc Natl Acad Sci USA 100, 9280-5 (2003
23. Kuznik A., et al. Mechanism of Endosomal TLR Inhibition by Antimalarial Drugs and Imidazoquinolines. J Immunol 186, 4794-4804 (2011
24. Schmid S., Fuchs R., Kielian M., Helenius A., & Mellman I. Acidification of endosome subpopulations in wild-type Chinese hamster ovary cells and temperature-sensitive acidification-defective mutants. J Cell Biol 108, 1291-300 (1989
25. Perez L., & Carrasco L. Involvement of the Vacuolar H+ -Atpase in Animal Virus Entry. J Gen Virol 75, 2595-2606 (1994
26. Li K. S., et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 430, 209-13 (2004
27. Gao R., et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 368, 1888-97 (2013
28. Gubareva L., et al. Update: Drug Susceptibility of Swine-Origin Influenza A (H1N1) Viruses, April 2009 (Reprinted from MMWR, vol 58, pg 433-435, 2009). J Am Med Assoc 301, 2086-2087 (2009
29. Smith A. E., & Helenius A. How viruses enter animal cells. Science 304, 237-42 (2004
30. Das K., Aramini J. M., Ma L. C., Krug R. M., & Arnold E. Structures of influenza A proteins and insights into antiviral drug targets. Nat Struct Mol Biol 17, 530-8 (2010
31. Zheng B., et al. D225G mutation in hemagglutinin of pandemic influenza H1N1 (2009) virus enhances virulence in mice. Exp Biol Med 235, 981-8 (2010
32. Zheng B. J., et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci USA 105, 8091-6 (2008
33. Zhong N. S., et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People?s Republic of China, in February, 2003. Lancet 362, 1353-8 (2003
34. Puigbo P., Guzman E., Romeu A., & Garcia-Vallve S. OPTIMIZER: a web server for optimizing the codon usage of DNA sequences. Nucleic acids research 35, W126-31 (2007
35. McCoy J., & La Ville E. Expression and purification of thioredoxin fusion proteins. Current protocols in protein science/editorial board, John E. Coligan ? [et al.] Chapter 6, Unit 6 7 (2001
36. Gong T., et al. Recombinant mouse beta-defensin 2 inhibits infection by influenza A virus by blocking its entry. Archives of virology 155, 491-8 (2010
37. Sui H. Y., et al. Small interfering RNA targeting m2 gene induces effective and long term inhibition of influenza A virus replication. PloS one 4, e5671 (2009
38. Pauwels R., et al. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 20, 309-21 (1988
39. Guan Y., et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302, 276-8 (2003
40. Du L., et al. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection. J Immunol 180, 948-56 (2008